VKTX
No price yet
Announcements
Nothing here yet
Daily updates
- Viking Therapeutics priced an expanded offering of 7.9M shares at $35 and $225M of 2.00% convertible notes due 2032 to fund VK2735, VK3019, R&D, and operations.Sep 25, 2026
- Viking Therapeutics reported encouraging VK2735 weight-management data showing subjects maintained up to 97% of prior weight loss with biweekly dosing after initial weekly treatment, while continued weekly dosing produced further weight reduction.Sep 22, 2026
FDA designations
Nothing here yet
News
- Viking Therapeutics reports positive topline results from the VK2735 GLP-1/GIP agonist maintenance study, supporting multiple maintenance dosing regimensSep 22, 2026
- Viking Therapeutics initiated a Phase 1 trial of the novel amylin receptor agonist VK3019 in healthy adultsJun 24, 2026
- Viking Therapeutics completed enrollment in Phase 3 VANQUISH-2 trial of VK2735Mar 26, 2026
- Viking Therapeutics published Phase 2 VENTURE trial results for VK2735 in Obesity journalJan 12, 2026
- Viking Therapeutics completed enrollment in VK2735 maintenance dosing trialJan 8, 2026